

L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:212840 CAPLUS Full-text

DN 144:267313

TI Novel compositions and methods of treatment of cellular proliferative diseases using quinazolinone derivs.

IN Auger, Kurt R.; Jackson, Jeffrey R.; Sutton, David

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006026597	A2	20060309	WO 2005-US30788	20050830
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-605549P P 20040830

US 2005-694531P P 20050628

AB Disclosed inter alia is the use of quinazolinone derivs., which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The quinazolinone derivs. are administered with another chemotherapeutic agent selected from alkylating agents, anti metabolites, platinating agents, topoisomerase inhibitors, tubulin agents and signaling inhibitors (e.g., kinase inhibitors). Pharmaceutical compns. comprising one or both types of active agents are also disclosed.

IT 514820-03-2

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel compns. and methods of treatment of cellular proliferative diseases using quinazolinone derivs.)

RN 514820-03-2 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 336113-53-2

CMF C30 H33 Cl N4 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1335155 CAPLUS Full-text  
 DN 144:74923  
 TI Compositions, devices and methods for treating cardiovascular disease  
 using KSP inhibitors  
 IN Malik, Fady; Bergnes, Gustave  
 PA USA  
 SO U.S. Pat. Appl. Publ., 18 pp.  
 CODEN: USXXCO

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005282834	A1	20051222	US 2005-147406	20050607
	WO 2005123083	A1	20051229	WO 2005-US19791	20050607
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-578755P P 20040609

OS MARPAT 144:74923


AB In situ drug-delivering medical devices, materials and associated compds., pharmaceutical compns. and methods are disclosed for the treatment of diseases of proliferating cells, particularly atherosclerosis and restenosis. The medical device or material comprising an effective amount of at least one inhibitor of kinesin spindle protein (KSP), especially human KSP (HsEg5). For example, a Paralene C/active agent solution was made by dissolving 1.75 mg/mL poly(ethylene-co-vinyl acetate), 1.75 mg/mL polybutyl methacrylate, and 1.5 mg/mL N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide in 50 mL MTBE, with stirring at room temperature. The stent was coated with the Paralene C/active agent solution using a vapor deposition method provided. The dried stent was weighed, the amount of Paralene C/active agent coating was determined as the difference between pre- and post-coating wts., and the dosage of active agent was calculated. The active agent-coated stent demonstrated continuous delivery of active agent into the release medium over the test period.

IT 336115-13-0 871672-12-7 871672-13-8  
 871672-14-9 871672-15-0 871672-16-1

RL: DEV (Device component use); PRP (Properties); THU (Therapeutic use);  
 BIOL (Biological study); USES (Uses)  
 (compns. and devices for sustained delivery of KSP inhibitors for  
 treating cardiovascular disease)


RN 336115-13-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 871672-12-7 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-3-fluoro-4-methyl- (9CI)  
(CA INDEX NAME)




RN 871672-13-8 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-(hydroxymethyl)- (9CI)  
(CA INDEX NAME)




RN 871672-14-9 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-[(phosphonoxy)methyl]- (9CI) (CA INDEX NAME)




RN 871672-15-0 CAPLUS

CN 2-Propenoic acid, 2-methyl-, [4-[[ (3-aminopropyl) [1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]amino]carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 871672-16-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl-N-[3-[(1-oxo-2-propenyl)amino]propyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1058193 CAPLUS Full-text  
 DN 143:454697  
 TI Development of a high-throughput robotic fluorescence-based assay for HsEg5 inhibitor screening  
 AU Zhang, Bin; Senator, David; Wilson, Christopher J.; Ng, Shi-Chung  
 CS Department of Chemical Genomics, ArQule Inc., Woburn, MA, 01801, USA  
 SO Analytical Biochemistry (2005), 345(2), 326-335  
 CODEN: ANBCA2; ISSN: 0003-2697  
 PB Elsevier  
 DT Journal  
 LA English  
 AB HsEg5 has microtubule-activated ATPase activity and plays essential roles in bipolar spindle formation. Because HsEg5 is validated as an attractive cancer target, in vitro biochem. assays have been developed for identifying compds. with high inhibitory activity. Several compds., including quinazoline ring-containing compds., have been identified and are currently in clin. trials. Although considerable progress has been made during recent years, limitations of HsEg5 in vitro screening assays still reside in two main aspects. First, colorimetric-based assays exhibit relatively low sensitivity and limited dynamic range that are unable to accurately measure compds. with nanomolar potencies. Second, current fluorescence assays are relatively low throughput without "mix and read" homogeneous features. In this study, the authors describe a sensitive fluorescence-based assay for HsEg5-specific inhibitors. By coupling several enzymes' activities, the release of ADP was measured quant. through red fluorescent resorufin. The Km for ATP hydrolysis in this assay was calculated as 23  $\mu$ M. The known HsEg5 inhibitors CK0106023 and CK0238273 gave IC50 values of 9.8 and 30.6 nM, resp. The authors' fluorescence assay has a 20-fold increase in sensitivity with broader dynamic range when compared with a colorimetric assay. The authors further automated this assay for high-throughput screening with a Z' factor of 0.8.  
 IT **514820-03-2**, CK-0238273 **709039-94-1**, R-CK0106023  
 RL: ANT (Analyte); ANST (Analytical study)  
 (inhibitor; development of high-throughput robotic fluorescence-based assay for HsEg5 kinesin ATPase inhibitor screening)  
 RN 514820-03-2 CAPLUS  
 CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 336113-53-2

CMF C30 H33 Cl N4 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 709039-94-1 CAPLUS

CN Benzamide, 4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:611678 CAPLUS Full-text  
 DN 143:103378  
 TI Implantable medical devices coated with kinesin spindle protein and biocompatible polymer to treat or inhibit restenosis  
 IN Hezi-Yamit, Ayala; Singh, Sabeena; Trudel, Julie  
 PA Medtronic Vascular, Inc., USA  
 SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Provisional Ser. No. 532,358.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005152940	A1	20050714	US 2004-996031	20041123
PRAI	US 2003-532358P	P	20031223		

AB Implantable medical devices having coatings of certain antiproliferative agents, particularly a certain kinesin spindle protein (KSP) inhibitor, are disclosed. The anti-restenotic KSP inhibitor is CK-0238273, and pharmaceutically acceptable derivs. thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. Moreover, medical devices composed entirely of biocompatible polymer-KSP inhibitor blends are disclosed. For example, a stent was coated with a mixture of 250 mg of CK-0238273 solution and 250 mg of polycaprolactone to achieve a final coating (drug plus polymer) weight of between about 10 µg and 1.0 mg. The ability of kinesin spindle protein inhibitor to reduce neointimal hyperplasia in response to intravascular stent placement in an acutely injured porcine coronary artery was demonstrated.

IT **514820-03-2**, CK 0238273  
 RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (CK 0238273; implantable medical devices coated with kinesin spindle protein inhibitor and biocompatible polymer to treat or inhibit restenosis)

RN 514820-03-2 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 336113-53-2

CMF C30 H33 Cl N4 O2

Absolute stereochemistry.






CM 2



CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:589184 CAPLUS Full-text  
 DN 143:127882  
 TI Genes correlated with sensitivity of human cancer cells to thiadiazoline  
 or cysteine derivative mitotic kinesin Eg5 inhibitors identified by  
 expression profiling  
 IN Shinohara, Fumikazu; Obayashi, Masaya; Yoshida, Tetsuo; Tsujita, Tetsuya;  
 Nakai, Ryuichiro; Yamashita, Yoshinori  
 PA Kyowa Hakko Kogyo Co., Ltd., Japan  
 SO PCT Int. Appl., 118 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061707	A1	20050707	WO 2004-JP19783	20041224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2003-428289	A	20031224		
OS	MARPAT 143:127882				
GI					



AB A method for identifying genes correlated with the sensitivity to of the  
 cancer cells Eg5 inhibitors, use of the genes identified or proteins encoded  
 by the genes for increasing the sensitivity of the cancer cells to the Eg5  
 inhibitor, or screening compds. having such effects, are disclosed. The  
 method comprises measuring the sensitivities to an Eg5 inhibitor of two or  
 more human cancer cell lines and the expression levels of one or more human

genes and identifying genes showing a correlation between its expression level and the sensitivity to the Eg5 inhibitor as genes correlated with the sensitivity to the Eg5 inhibitor. Thiadiazoline derivs. are represented by the general formula (I) and pharmacol. acceptable salts thereof [R1, R4 = H, each (un)substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, or heterocyclyl; R2 = R1, R4, C(=W)R6, (un)substituted NH2; W = O, S; R6 = R1, R4, (un)substituted NH2, etc.; or -NR1R4; -OR1; -SR1; -NR11R12 (R11 and R12 same or -C(=O)R13 (where R13 = R1, -NR7R8, -OR9A, or -SR10A), or -SO2R1; R5 = each (un)substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, or heterocyclyl; or R4 and R5 are joined together to form (CR15AR15B)m1-Q-(CR15cR15D)m2; Q = single bond, each (un)substituted phenylene or cycloalkylene; m1, m2 = 0-4; R15A, R15B, R15c, R15D = H, halo, (un)substituted lower alkyl, -OR16, -CONR7BR8B, -SO2NR7BR8B, -COR17, -NR18R19, -COR20, -SO2R21, -CO2R22, all groups same as R5); R3 = H, C(=W)R6]. Eg5 inhibitors may also be cysteine derivs. II (R24 = (un)substituted aryl, aromatic heterocyclyl; R25, R26 = O, halo, lower alkyl, lower alkoxy, OH, CO2H, CH2OH, or together O, S, or a bond). These compds. inhibit mitotic kinesin Eg5 in G2/M phase of the cell cycle and are useful as antitumor agents for treating malignant tumors.


IT 336113-53-2

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cysteine derivs.; genes correlated with sensitivity of human cancer cells to thiadiazoline or cysteine derivative mitotic kinesin Eg5 inhibitors identified by expression profiling)

RN 336113-53-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:490357 CAPLUS Full-text  
 DN 143:43896  
 TI Preparation of quinazolinone compounds as anticancer agents  
 IN Wang, Weibo; Lagniton, Liana M.; Constantine, Ryan N.; Desai, Manoj C.  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051922	A1	20050609	WO 2004-US39448	20041124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005209254	A1	20050922	US 2004-996814	20041124
PRAI	US 2003-525059P	P	20031125		
OS	MARPAT 143:43896				
GI					



AB Title compds. I [X = O, S; R1 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R2 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R3 = CO2R10, COR10, CONR11R12, etc.; R10, R11, R12 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R4 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R5 = H, (un)substituted alkyl, (un)substituted alkoxy, etc.; R6, R7, R8, R9 = H, halo, hydroxy, etc.] and their pharmaceutically acceptable salts were prepared For example, 4-methylbenzoylation of compound I [X = O; R1 = benzyl; R2 = H; R3 = CONMe2; R4 = 3-(tert-butoxycarbonylamino)propyl; R5 = H; R7 = Cl; R6 = R8 = R9 = H], e.g., prepared from 2-amino-4-chlorobenzoic acid in 4 steps, followed by treatment with trifluoroacetic acid afforded compound I [X = O; R1 = benzyl; R2 = H; R3 = CONMe2; R4 = 3-aminopropyl; R5 = 4-methylbenzoyl; R7 = Cl; R6 = R8 = R9 = H]. Compds. I are claimed useful as KSP (kinesin spindle protein) inhibitors for the treatment of cancer.  
 IT 853302-69-9P 853302-70-2P 853302-71-3P


853302-72-4P 853302-73-5P 853302-74-6P  
 853302-75-7P 853302-76-8P 853302-77-9P  
 853302-78-0P 853302-79-1P 853302-80-4P  
 853302-81-5P 853302-82-6P 853302-83-7P  
 853302-84-8P 853302-85-9P 853302-86-0P  
 853302-87-1P 853302-88-2P 853302-89-3P  
 853302-90-6P 853302-91-7P 853302-92-8P  
 853302-93-9P 853302-94-0P 853302-95-1P  
 853302-96-2P 853302-97-3P 853302-98-4P  
 853302-99-5P 853303-00-1P 853303-01-2P  
 853303-02-3P 853303-03-4P 853303-04-5P  
 853303-05-6P 853303-06-7P 853303-07-8P  
 853303-08-9P 853303-09-0P 853303-10-3P  
 853303-12-5P 853303-13-6P 853303-14-7P  
 853303-15-8P 853303-16-9P 853303-29-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinone compds. as KSP inhibitors for treatment of cancer)


RN 853302-69-9 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(4-bromobenzoyl)[3-(dimethylamino)propyl]amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-70-2 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(4-bromobenzoyl)[3-(dimethylamino)propyl]amino]-7-chloro- $\alpha$ -ethyl-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-71-3 CAPLUS

CN 2-Quinazolineacetic acid, 7-chloro- $\alpha$ -[[3-(dimethylamino)propyl](4-methylbenzoyl)amino]-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-72-4 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(3-bromobenzoyl)[3-(dimethylamino)propyl]amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-73-5 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(2-bromobenzoyl)[3-(dimethylamino)propyl]amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-74-6 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-75-7 CAPLUS

CN 2-Quinazolineacetic acid, 7-chloro- $\alpha$ -[[3-(dimethylamino)propyl](3-methylbenzoyl)amino]-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-76-8 CAPLUS

CN 2-Quinazolineacetic acid, 7-chloro- $\alpha$ -[[3-(dimethylamino)propyl](2-methylbenzoyl)amino]-3,4-dihydro-4-oxo-3-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 853302-77-9 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(4-bromobenzoyl)[3-(dimethylamino)propyl]amino]-7-chloro-N-ethyl-3,4-dihydro-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 853302-78-0 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(4-bromobenzoyl)[3-(dimethylamino)propyl]amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 853302-79-1 CAPLUS

CN 2-Quinazolineacetic acid, 7-chloro- $\alpha$ -[[3-(dimethylamino)propyl](4-methylbenzoyl)amino]-3,4-dihydro-4-oxo-3-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 853302-80-4 CAPLUS

CN 2-Quinazolineacetic acid,  $\alpha$ -[(3-aminopropyl)(4-bromobenzoyl)amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 853302-81-5 CAPLUS


CN 2-Quinazolineacetic acid,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)






RN 853302-82-6 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-bromobenzoyl)amino]-7-chloro-N,N-diethyl-3,4-dihydro-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 853302-83-7 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-N,N-diethyl-3,4-dihydro-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 853302-84-8 CAPLUS


CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 853302-85-9 CAPLUS


CN Benzamide, N-(3-aminopropyl)-4-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-

(phenylmethyl)-2-quinazolinyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 853302-86-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 853302-87-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-4-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 853302-88-2 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-bromobenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 853302-89-3 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-chlorobenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 853302-90-6 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-oxo-2-(1-pyrrolidinyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 853302-91-7 CAPLUS


CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-

chloro-3,4-dihydro-N,N-dimethyl-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 853302-92-8 CAPLUS

CN 2-Quinazolineacetamide, α-[(3-aminopropyl)(4-methylbenzoyl)amino]-3-[(2-bromophenyl)methyl]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 853302-93-9 CAPLUS

CN 2-Quinazolineacetamide, α-[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(2-chlorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 853302-94-0 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(3-chlorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853302-95-1 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(3-fluorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853302-96-2 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-3-[(3-methylphenyl)methyl]-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853302-97-3 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 853302-98-4 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(4-chlorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




RN 853302-99-5 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(2,5-dichlorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 853303-00-1 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(2,6-dichlorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 853303-01-2 CAPLUS


CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-3-[(3-methoxyphenyl)methyl]-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 853303-02-3 CAPLUS


CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-

chloro-3,4-dihydro-N,N-dimethyl-3-(2-naphthalenylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 853303-03-4 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo-3-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 853303-04-5 CAPLUS



CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo-3-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 853303-05-6 CAPLUS


CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI) (CA INDEX NAME)






RN 853303-06-7 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-3-[(3-hydroxyphenyl)methyl]-N,N-dimethyl-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853303-07-8 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853303-08-9 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-3-  
([1,1'-biphenyl]-3-ylmethyl)-7-chloro-3,4-dihydro-N,N-dimethyl-4-oxo-  
(9CI) (CA INDEX NAME)




RN 853303-09-0 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-  
chloro-3-[(3-cyanophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853303-10-3 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-  
chloro-3-[(3-nitrophenyl)methyl]-4-oxo- (9CI)  
(CA INDEX NAME)




RN 853303-12-5 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(3,4-dichlorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo-(9CI) (CA INDEX NAME)




RN 853303-13-6 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-N-ethyl-3,4-dihydro-N-methyl-4-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 853303-14-7 CAPLUS


CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(3,5-dimethylphenyl)methyl]-N-ethyl-3,4-dihydro-N-methyl-4-oxo-(9CI) (CA INDEX NAME)



RN 853303-15-8 CAPLUS


CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-

chloro-N-ethyl-3,4-dihydro-3-[(3-methoxyphenyl)methyl]-N-methyl-4-oxo-  
(9CI) (CA INDEX NAME)



RN 853303-16-9 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3-[(3,5-difluorophenyl)methyl]-3,4-dihydro-N,N-dimethyl-4-oxo-  
(9CI) (CA INDEX NAME)




RN 853303-29-4 CAPLUS

CN 2-Quinazolineacetamide,  $\alpha$ -[(3-aminopropyl)(4-methylbenzoyl)amino]-7-chloro-3,4-dihydro-N,N-dimethyl-3-[(3-methylphenyl)methyl]-4-oxo-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 853302-96-2


CMF C31 H34 Cl N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 853303-23-8 853303-30-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazolinone compds. as KSP inhibitors for treatment of cancer)


RN 853303-23-8 CAPLUS

CN Carbamic acid, [3-[[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(dimethylamino)-2-oxoethyl](4-methylbenzoyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 853303-30-7 CAPLUS

CN Carbamic acid, [3-[[1-[7-chloro-3,4-dihydro-3-[(3-methylphenyl)methyl]-4-oxo-2-quinazolinyl]-2-(dimethylamino)-2-oxoethyl](4-methylbenzoyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:363268 CAPLUS Full-text  
 DN 141:46875  
 TI Antitumor Activity of a Kinesin Inhibitor  
 AU Sakowicz, Roman; Finer, Jeffrey T.; Beraud, Christophe; Crompton, Anne; Lewis, Evan; Fritsch, Alex; Lee, Yan; Mak, John; Moody, Robert; Turincio, Rebecca; Chabala, John C.; Gonzales, Paul; Roth, Stephanie; Weitman, Steve; Wood, Kenneth W.  
 CS Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA  
 SO Cancer Research (2004), 64(9), 3276-3280  
 CODEN: CNREA8; ISSN: 0008-5472  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB Several members of the kinesin family of microtubule motor proteins play essential roles in mitotic spindle function and are potential targets for the discovery of novel antimitotic cancer therapies. KSP, also known as HsEg5, is a kinesin that plays an essential role in formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. We identified a potent inhibitor of KSP, CK0106023, which causes mitotic arrest and growth inhibition in several human tumor cell lines. Here we show that CK0106023 is an allosteric inhibitor of KSP motor domain ATPase with a  $K_i$  of 12 nM. Among five kinesins tested, CK0106023 was specific for KSP. In tumor-bearing mice, CK0106023 exhibited antitumor activity comparable to or exceeding that of paclitaxel and caused the formation of monopolar mitotic figures identical to those produced in cultured cells. KSP was most abundant in proliferating human tissues and was absent from cultured postmitotic neurons. These findings are the first to demonstrate the feasibility of targeting mitotic kinesins for the treatment of cancer.  
 IT **336115-72-1**, CK 0106023 **708296-51-9 709039-94-1**  
 , (R)-CK 0106023  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antitumor activity of kinesin inhibitor)  
 RN 336115-72-1 CAPLUS  
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 708296-51-9 CAPLUS  
 CN Benzamide, 4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 709039-94-1 CAPLUS

CN Benzamide, 4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 28

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:678784 CAPLUS Full-text  
 DN 139:214481  
 TI Syntheses of enantiomerically pure quinazolinones  
 IN Bergnes, Gustav; Ha, Edward; Yiannikourous, George; Kalaritis, Panos;  
 Yonce, Brandon E.; Weldon, Kurt Alan, Jr.  
 PA Cytokinetics, Inc., USA; SmithKline Beecham Corp.  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070701	A2	20030828	WO 2003-US4713	20030214
	WO 2003070701	A3	20031016		
	WO 2003070701	B1	20031218		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2475879	AA	20030828	CA 2003-2475879	20030214
	AU 2003213092	A1	20030909	AU 2003-213092	20030214
	US 2004067969	A1	20040408	US 2003-366828	20030214
	US 7009049	B2	20060307		
	EP 1480980	A2	20041201	EP 2003-709135	20030214
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005529076	T2	20050929	JP 2003-569608	20030214
	US 2006041130	A1	20060223	US 2005-254211	20051020
PRAI	US 2002-357244P	P	20020215		
	US 2002-380746P	P	20020514		
	US 2003-366828	A3	20030214		
	WO 2003-US4713	W	20030214		
OS	MARPAT 139:214481				
GI					




AB The present invention provides intermediates, synthetic methods and novel quinazolinone (shown as I; e.g. (R)-N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide) compns. of matter, which are inhibitors of the mitotic kinesin KSP (no data) and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation (no data); only the compds., compns. of matter and synthetic methods are claimed. The method comprises contacting HO2CCH(R2)NHX (R2 = oxaalkyl or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or



alkylheteroaryl; X = H, protecting group (e.g. Boc, CBZ, phthalide, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl); e.g. valine) with iso-Bu chloroformate followed by contacting the resulting product with (un)substituted 2-aminobenzoic acids to give I. Eight example preps. of I are included. For example, (S)-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester was prepared starting from N-Boc-L-valine and involving intermediates 2-[[2-[(tert-butoxycarbonyl)amino]-L-3-methylbutyryl]amino]-4-chlorobenzoic acid, (S)-[1-(7-chloro-4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester, (S)-[1-[[2-benzylcarbamoyle-5-chlorophenyl]imino]methyl]-2-methylpropyl]carbamic acid tert-Bu ester (in mixture with the final product). In the key step, to 2-[[2-[(tert-butoxycarbonyl)amino]-L-3-methylbutyryl]amino]-4-chlorobenzoic acid was added 13.2 mL (0.1 mol) of iso-Bu chloroformate over 15 min (internal temperature 5°) followed by the addition of 11.1 mL (0.1 mol) of anhydrous N-methylmorpholine over 15 min at 0°; the mixture was stirred for an addnl. hour at 0° to give (S)-[1-(7-chloro-4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester. For I: R1 is H or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; R3 is H, oxaalkyl, R9O-, R9NH- or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, or oxaalkylaryl; R4 is H or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; R5, R6, R7 and R8 = H, hydroxy, (un)substituted alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, amino, alkylamino, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl or heteroaryl; and R9 is (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl. The comps. of matter comprise I and detectable amts. of ≥1 unreacted starting materials and/or a cyclo-dehydration reagent; they are claimed, presumably because it is important to monitor the purity of pharmaceutical compds. for the presence of such materials, which presence comprises a way of detecting use of a process of the invention.

- IT **336113-53-2P**, (R)-N-(3-Aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide  
**587881-28-5P**, (R)-[3-[[1-(3-Benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl](4-methylbenzoyl)amino]propyl]carbamic acid tert-butyl ester  
 RL: RCT (Reactant); PREP (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (syntheses of enantiomerically pure quinazolinones)  
 RN 336113-53-2 CAPLUS  
 CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587881-28-5 CAPLUS

CN Carbamic acid, [3-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl](4-methylbenzoyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **336113-54-3P**, (S)-N-(3-Aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide  
**587881-21-8P**, (R)-N-(3-Aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide mesylate  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(syntheses of enantiomerically pure quinazolinones)

RN 336113-54-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 587881-21-8 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 336113-53-2

CMF C30 H33 Cl N4 O2


Absolute stereochemistry.



CM 2



CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:417728 CAPLUS Full-text  
 DN 139:6884  
 TI Process for the racemization of chiral quinazolinones  
 IN Yao, Bing; Smith, Whitney W.; Bergnes, Gustave; Morgans, David, Jr.  
 PA Cytokinetics, Inc., USA  
 SO PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003043995	A1	20030530	WO 2002-US37410	20021120
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002346471	A1	20030610	AU 2002-346471	20021120
	US 2003166933	A1	20030904	US 2002-300967	20021120
	US 6753428	B2	20040622		
	US 2004192913	A1	20040930	US 2004-773602	20040206
PRAI	US 2001-332148P	P	20011120		
	US 2002-300967	A1	20021120		
	WO 2002-US37410	W	20021120		
OS	MARPAT 139:6884				
GI					



AB Racemates were obtained from one of the enantiomers, or an enantiomerically enriched mixture, of an optically active quinazolinone derivative I [wherein R1 = H or (un)substituted alkyl, (hetero)aryl, or (hetero)aralkyl; R2 = oxaalkyl or (un)substituted alkyl, (hetero)aryl, or (hetero)aralkyl; R5-R8 = independently H, (fluoro)alkyl, alkoxy, halo, NO2, dialkylamino, alkylsulfonyl, alkylsulfamido(alkyl), sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, or (hetero)aryl] by reaction of the compound with an alkali alkoxide of a primary alc. and isolation of the racemate. For example, treatment of (S)-II with NaOEt (21% by weight solution in denatured alc. containing 5% toluene) in absolute EtOH and heating at reflux for 36 h, followed by crystallization gave (±)-II in a 1:1.1 mixture of (R)- and (S)-isomers. The invention also provides for the subsequent resolution of the racemate and use of the other enantiomer in the synthesis of pharmacol. active therapeutic agents. Thus, an efficient method of converting an inactive or undesirable enantiomer into the other usable, desirable enantiomer is disclosed.


IT 336113-50-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(intermediate; preparation and racemization of chiral quinazolinones)

RN 336113-50-9 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-  
N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




IT 533926-44-2P

RL: IMF (Industrial manufacture); PREP (Preparation)

(racemate; preparation and racemization of chiral quinazolinones)

RN 533926-44-2 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-  
quinazolinyl]-2-methylpropyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX  
NAME)



IT 533926-43-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(undesirable enantiomer; preparation and racemization of chiral  
quinazolinones)

RN 533926-43-1 CAPLUS

CN Benzamide, 4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-  
2-quinazolinyl]-2-methylpropyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:935583 CAPLUS Full-text  
 DN 136:53759  
 TI Preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors  
 IN Finer, Jeffrey T.; Bergnes, Gustav; Feng, Bainian; Smith, Whitney W.;  
 Chabala, John C.; Morgans, David J., Jr.  
 PA Cytokinetics, Inc., USA  
 SO PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098278	A1	20011227	WO 2001-US13901	20010427
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6545004	B1	20030408	US 2000-699047	20001024
	JP 2003048881	A2	20030221	JP 2002-156766	20001026
	US 6562831	B1	20030513	US 2000-724644	20001128
	US 6630479	B1	20031007	US 2000-724713	20001128
	US 6831085	B1	20041214	US 2000-724941	20001128
	CA 2413426	AA	20011227	CA 2001-2413426	20010427
	EP 1296959	A1	20030402	EP 2001-932769	20010427
	EP 1296959	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011898	A	20030513	BR 2001-11898	20010427
	JP 2004501140	T2	20040115	JP 2002-504234	20010427
	NZ 523233	A	20041029	NZ 2001-523233	20010427
	ZA 2002010133	A	20030617	ZA 2002-10133	20021213
	NO 2002006172	A	20030220	NO 2002-6172	20021220
	US 2004023996	A1	20040205	US 2003-312323	20030815
	US 2004254203	A1	20041216	US 2004-893929	20040720
	US 2005187232	A1	20050825	US 2005-84787	20050321
PRAI	US 2000-213104P	P	20000621		
	US 2000-699047	A	20001024		
	US 1999-198253P	P	19991027		
	JP 2001-533122	A3	20001026		
	US 2000-724778	A3	20001128		
	US 2000-724941	A3	20001128		
	WO 2001-US13901	W	20010427		

OS MARPAT 136:53759  
 GI



AB R1CR2R2'NRR4 [I; R = H, COR3, SO2R3', CH2R3''; R1 = (un)substituted 3,4-dihydro-4-oxoquinazolin-2-yl; R2,R2' = H, (oxa)alkyl, (hetero)aryl, etc.; R3 =

H, alkyl, alkoxy, (hetero)aryl, etc.; R3',R4 = H, alkyl, (hetero)aryl, etc.; R3'' = alkyl, (hetero)aryl, etc.] were prepared. Thus, 2-(H2N)C6H4CO2H was amidated by PrCOCl and the cyclized product cyclocondensed with PhCH2NH2 to give, after bromination, quinazolinone II (R = Br) which was converted in 2 steps to II [R = N(COC6H4F-4)CH2CH2NMe2]. Data for biol. activity of I were given.

IT 334003-55-3P 334488-92-5P 334488-97-0P  
 334488-98-1P 334488-99-2P 334489-01-9P  
 336113-50-9P 336113-53-2P 336113-54-3P  
 336113-59-8P 336113-60-1P 336113-61-2P  
 336113-62-3P 336113-63-4P 336113-64-5P  
 336113-65-6P 336113-66-7P 336113-67-8P  
 336113-68-9P 336113-69-0P 336113-70-3P  
 336113-71-4P 336113-72-5P 336113-73-6P  
 336113-88-3P 336114-22-8P 336115-02-7P  
 336115-04-9P 336115-06-1P 336115-09-4P  
 336115-11-8P 336115-13-0P 336115-15-2P  
 336115-17-4P 336115-19-6P 336115-22-1P  
 336115-24-3P 336115-26-5P 336115-28-7P  
 336115-30-1P 336115-32-3P 336115-36-7P  
 336115-38-9P 336115-40-3P 336115-44-7P  
 336115-46-9P 336115-48-1P 336115-56-1P  
 336115-58-3P 336115-60-7P 336115-62-9P  
 336115-66-3P 336115-72-1P 336115-74-3P  
 336115-82-3P 336115-86-7P 336115-95-8P  
 336115-97-0P 336115-99-2P 336116-03-1P  
 336116-07-5P 336116-09-7P 336116-13-3P  
 336116-17-7P 336116-19-9P 336116-23-5P  
 336116-25-7P 336116-27-9P 336116-29-1P  
 336116-31-5P 336116-33-7P 336116-35-9P  
 336116-37-1P 336116-39-3P 336116-41-7P  
 336116-43-9P 336116-45-1P 336116-47-3P  
 336116-49-5P 336116-53-1P 336116-55-3P  
 336116-57-5P 336116-65-5P 336116-67-7P  
 336116-69-9P 336116-73-5P 336116-75-7P  
 336116-77-9P 336116-79-1P 336116-81-5P  
 336116-83-7P 336116-87-1P 336116-89-3P  
 336116-91-7P 336116-95-1P 336116-97-3P  
 336117-01-2P 336117-03-4P 336117-07-8P  
 336117-09-0P 336117-13-6P 336117-21-6P  
 336117-24-9P 336117-26-1P 336117-28-3P  
 336117-32-9P 336117-34-1P 336117-36-3P  
 336117-40-9P 336117-42-1P 336117-44-3P  
 336117-48-7P 336117-50-1P 336117-52-3P  
 336117-54-5P 336117-56-7P 336117-60-3P  
 336117-62-5P 336117-65-8P 336117-67-0P  
 336117-71-6P 336117-84-1P 336117-86-3P  
 336118-06-0P 336118-27-5P 336118-30-0P  
 336118-32-2P 336118-34-4P 336118-36-6P  
 336118-39-9P 336118-43-5P 336118-45-7P  
 336118-49-1P 336118-59-3P 336118-61-7P  
 336118-64-0P 336118-74-2P 336118-76-4P  
 336118-88-8P 336119-03-0P 336119-17-6P  
 336119-19-8P 336119-23-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors)

RN 334003-55-3 CAPLUS


CN Benzamide, 3-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-

quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 334488-92-5 CAPLUS

CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 334488-97-0 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 334488-98-1 CAPLUS


CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)






RN 334488-99-2 CAPLUS

CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 334489-01-9 CAPLUS

CN Benzamide, 4-butyl-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336113-50-9 CAPLUS


CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 336113-53-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-54-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-59-8 CAPLUS

CN Benzamide, 4-bromo-N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-60-1 CAPLUS


CN Benzamide, 4-bromo-N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-61-2 CAPLUS


CN 1-Naphthalenecarboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336113-62-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-63-4 CAPLUS


CN 1-Naphthalenecarboxamide, N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-64-5 CAPLUS


CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336113-65-6 CAPLUS

CN Benzamide, 4-bromo-N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-66-7 CAPLUS

CN Benzamide, 4-bromo-N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-67-8 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-68-9 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-69-0 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-70-3 CAPLUS


CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-71-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336113-72-5 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-73-6 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336113-88-3 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 336114-22-8 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 336115-02-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[3-[(1-methylethyl)amino]propyl]- (9CI)  
(CA INDEX NAME)




RN 336115-04-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(4-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336115-06-1 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-methyl- (9CI) (CA INDEX NAME)





RN 336115-09-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-3-[(3-methoxyphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-11-8 CAPLUS


CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336115-13-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-15-2 CAPLUS

CN Benzamide, N-(3-azetidinemethyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-17-4 CAPLUS

CN Benzamide, N-(2-aminoethyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-19-6 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-22-1 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336115-24-3 CAPLUS  
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(methylamino)propyl]- (9CI) (CA INDEX NAME)




RN 336115-26-5 CAPLUS  
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-28-7 CAPLUS  
 CN Benzamide, N-[(2R)-2-azetidinemethyl]-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 336115-30-1 CAPLUS  
 CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-32-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(methylthio)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-36-7 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-38-9 CAPLUS


CN Benzamide, 4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336115-40-3 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-44-7 CAPLUS

CN Benzamide, N-(4-aminobutyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-46-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(3-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-48-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-56-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-58-3 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-60-7 CAPLUS

CN Benzamide, 4-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-62-9 CAPLUS

CN Benzamide, N-(4-aminobutyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-66-3 CAPLUS

CN Benzamide, N-[3-(1-azetidiny)propyl]-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-72-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 336115-74-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]butyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336115-82-3 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylthio)propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-86-7 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336115-95-8 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)






RN 336115-97-0 CAPLUS

CN Benzamide, N-(5-aminopentyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-99-2 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-03-1 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-07-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-09-7 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(diethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 336116-13-3 CAPLUS

CN Carbamic acid, [5-[(3-aminopropyl)(4-methylbenzoyl)amino]-5-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 336116-17-7 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-19-9 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-cyclohexylethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-23-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(3-hydroxypropyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-25-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336116-27-9 CAPLUS

CN Benzamide, N-(6-aminohexyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-29-1 CAPLUS

CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-31-5 CAPLUS

CN Benzamide, 4-bromo-N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-33-7 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 336116-35-9 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-37-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-39-3 CAPLUS

CN Benzamide, N-[5-amino-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]pentyl]-N-(3-aminopropyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-41-7 CAPLUS

CN Benzamide, N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-43-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-3-[(3-methylphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-45-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-47-3 CAPLUS

CN  $\beta$ -Alanine, N-(4-bromobenzoyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-49-5 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
(CA INDEX NAME)




RN 336116-53-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 336116-55-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
(CA INDEX NAME)




RN 336116-57-5 CAPLUS

CN Benzamide, 3-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-65-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336116-67-7 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 336116-69-9 CAPLUS




CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-7-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-73-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 336116-75-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-77-9 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-79-1 CAPLUS

CN Benzamide, 4-bromo-N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-81-5 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(phenylmethoxy)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-83-7 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylsulfinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-87-1 CAPLUS  
 CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-89-3 CAPLUS  
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 336116-91-7 CAPLUS  
 CN Benzamide, 3,4-dichloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-95-1 CAPLUS  
 CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-97-3 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)




RN 336117-01-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-3-[(4-methoxyphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-03-4 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(methylsulfinyl)ethyl]-4-methyl- (9CI)  
(CA INDEX NAME)




RN 336117-07-8 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336117-09-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-hydroxyethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-13-6 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336117-21-6 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336117-24-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(2-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-26-1 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-28-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[1-cyclohexyl-4-(diethylamino)butyl]- (9CI) (CA INDEX NAME)




RN 336117-32-9 CAPLUS

CN Benzamide, N-(2-aminoethyl)-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-34-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-36-3 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-fluoro-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-40-9 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-42-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 336117-44-3 CAPLUS


CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)






RN 336117-48-7 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-50-1 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-4-fluoro-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-52-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[4-(diethylamino)-1-methylbutyl]- (9CI) (CA INDEX NAME)




RN 336117-54-5 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-7-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-56-7 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-60-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-62-5 CAPLUS

CN 6-Quinolinecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-65-8 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 336117-67-0 CAPLUS

CN Benzamide, 4-bromo-N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-71-6 CAPLUS

CN Benzamide, 3-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-84-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 336117-86-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
(CA INDEX NAME)




RN 336118-06-0 CAPLUS

CN Benzamide, 3-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336118-27-5 CAPLUS


CN Benzamide, 4-cyano-N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 336118-30-0 CAPLUS


CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-

N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336118-32-2 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-34-4 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 336118-36-6 CAPLUS

CN Benzamide, 4-cyano-N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336118-39-9 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 336118-43-5 CAPLUS


CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336118-45-7 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-3-[(2-methylphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

NAME)




RN 336118-49-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336118-59-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-61-7 CAPLUS

CN Carbamic acid, [3-[(4-bromobenzoyl)[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 336118-64-0 CAPLUS

CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-74-2 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336118-76-4 CAPLUS


CN 2-Naphthalenecarboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)






RN 336118-88-8 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 336119-03-0 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 336119-17-6 CAPLUS

CN  $\beta$ -Alanine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 336119-19-8 CAPLUS

CN Glycine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 336119-23-4 CAPLUS


CN Benzoic acid, 4-[[[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl][2-(dimethylamino)ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:319882 CAPLUS Full-text  
 DN 134:326543  
 TI Methods and compositions utilizing quinazolinones as KSP kinesin  
 modulators  
 IN Finer, Jeffrey T.; Bergnes, Gustave; Feng, Bainian; Smith, Whitney W.;  
 Chabala, John C.  
 PA Cytokinetics, Inc., USA  
 SO PCT Int. Appl., 168 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030768	A1	20010503	WO 2000-US29585	20001026
	WO 2001030768	C2	20020815		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2388646	AA	20010503	CA 2000-2388646	20001026
	BR 2000015110	A	20020702	BR 2000-15110	20001026
	EP 1226129	A1	20020731	EP 2000-976656	20001026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003048881	A2	20030221	JP 2002-156766	20001026
	JP 2003512461	T2	20030402	JP 2001-533122	20001026
	NZ 518480	A	20040227	NZ 2000-518480	20001026
	AU 774748	B2	20040708	AU 2001-14398	20001026
	US 6562831	B1	20030513	US 2000-724644	20001128
	US 6630479	B1	20031007	US 2000-724713	20001128
	US 6831085	B1	20041214	US 2000-724941	20001128
	ZA 2002002930	A	20021028	ZA 2002-2930	20020415
	NO 2002001907	A	20020607	NO 2002-1907	20020423
	ZA 2002010133	A	20030617	ZA 2002-10133	20021213
	NZ 530074	A	20050324	NZ 2003-530074	20031210
	US 2004254203	A1	20041216	US 2004-893929	20040720
	AU 2004218601	A1	20041028	AU 2004-218601	20041004
	US 2005187232	A1	20050825	US 2005-84787	20050321
PRAI	US 1999-198253P	P	19991027		
	US 2000-213104P	P	20000621		
	US 2000-699047	A1	20001024		
	JP 2001-533122	A3	20001026		
	WO 2000-US29585	W	20001026		
	US 2000-724778	A3	20001128		
	US 2000-724941	A3	20001128		
OS	MARPAT 134:326543				
GI					



I



II

AB Quinazolinones (I) [wherein R1 = H, alkyl, (hetero)aryl, or (un)substituted alkyl(hetero)aryl; R2 and R2a = independently H or (un)substituted (oxa)alkyl, (hetero)aryl, or alkyl(hetero)aryl; Y = NR4COR3, NR4SO2R3a, NR4CH2R3b, or NHR4; R3 = H, oxaalkyl, or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, oxaalkylaryl, ether, or amino; R3a = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or amino; R3b = (un)substituted alkyl, (hetero)aryl, or alkyl(hetero)aryl; R4 = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or alkylene; R5-R8 = independently H, (fluoro)alkyl, alkoxy, halo, NO2, dialkylamino, alkylsulfonyl, alkylsulfonamido(alkyl or aryl), alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, or (hetero)aryl] were prepared by conventional and solid phase combinatorial synthetic methods as KSP kinesin inhibitors for treatment of cellular proliferative diseases. For example, II was synthesized in a 6-step sequence involving (1) amidation of anthranilic acid with butyryl chloride (65%), (2) cyclization to give 2-propyl-3,1-[4H]benzoxazin-4-one (62%), (3) treatment with PhCH2NH2 to give 2-propyl-3-benzylquinazolin-4-one (67%), bromination (92%), addition of N,N-dimethylethylenediamine (55%), and (6) amidation with p-fluorobenzoyl chloride (65%). I are useful for treating cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders, and inflammation (no data). Methods of screening for compds. that will bind to a KSP kinesin or are modulators of KSP kinesin activity are also disclosed.


IT **336115-13-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)

RN 336115-13-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)



IT **334003-55-3P 334488-92-5P 334488-97-0P**  
**334488-98-1P 334488-99-2P 334489-01-9P**  
**336113-50-9P 336113-53-2P 336113-54-3P**


336113-59-8P 336113-60-1P 336113-61-2P  
 336113-62-3P 336113-63-4P 336113-64-5P  
 336113-65-6P 336113-66-7P 336113-67-8P  
 336113-68-9P 336113-69-0P 336113-70-3P  
 336113-71-4P 336113-72-5P 336113-73-6P  
 336113-88-3P 336114-22-8P 336115-02-7P  
 336115-04-9P 336115-06-1P 336115-09-4P  
 336115-11-8P 336115-15-2P 336115-17-4P  
 336115-19-6P 336115-22-1P 336115-24-3P  
 336115-26-5P 336115-28-7P 336115-30-1P  
 336115-32-3P 336115-36-7P 336115-38-9P  
 336115-40-3P 336115-44-7P 336115-46-9P  
 336115-48-1P 336115-56-1P 336115-58-3P  
 336115-60-7P 336115-62-9P 336115-66-3P  
 336115-72-1P 336115-74-3P 336115-82-3P  
 336115-86-7P 336115-95-8P 336115-97-0P  
 336115-99-2P 336116-03-1P 336116-07-5P  
 336116-09-7P 336116-13-3P 336116-17-7P  
 336116-19-9P 336116-23-5P 336116-25-7P  
 336116-27-9P 336116-29-1P 336116-31-5P  
 336116-33-7P 336116-35-9P 336116-37-1P  
 336116-39-3P 336116-41-7P 336116-43-9P  
 336116-45-1P 336116-47-3P 336116-49-5P  
 336116-53-1P 336116-55-3P 336116-57-5P  
 336116-65-5P 336116-67-7P 336116-69-9P  
 336116-73-5P 336116-75-7P 336116-77-9P  
 336116-79-1P 336116-81-5P 336116-83-7P  
 336116-87-1P 336116-89-3P 336116-91-7P  
 336116-95-1P 336116-97-3P 336117-01-2P  
 336117-03-4P 336117-07-8P 336117-09-0P  
 336117-13-6P 336117-21-6P 336117-24-9P  
 336117-26-1P 336117-28-3P 336117-32-9P  
 336117-34-1P 336117-36-3P 336117-40-9P  
 336117-42-1P 336117-44-3P 336117-48-7P  
 336117-50-1P 336117-52-3P 336117-54-5P  
 336117-56-7P 336117-60-3P 336117-62-5P  
 336117-65-8P 336117-67-0P 336117-71-6P  
 336117-84-1P 336117-86-3P 336118-06-0P  
 336118-27-5P 336118-30-0P 336118-32-2P  
 336118-34-4P 336118-36-6P 336118-39-9P  
 336118-41-3P 336118-43-5P 336118-45-7P  
 336118-49-1P 336118-59-3P 336118-61-7P  
 336118-64-0P 336118-74-2P 336118-76-4P  
 336118-88-8P 336119-03-0P 336119-17-6P  
 336119-19-8P 336119-23-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)


RN 334003-55-3 CAPLUS

CN Benzamide, 3-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 334488-92-5 CAPLUS

CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 334488-97-0 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 334488-98-1 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 334488-99-2 CAPLUS

CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 334489-01-9 CAPLUS

CN Benzamide, 4-butyl-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336113-50-9 CAPLUS


CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 336113-53-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-54-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-59-8 CAPLUS

CN Benzamide, 4-bromo-N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336113-60-1 CAPLUS

CN Benzamide, 4-bromo-N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 336113-61-2 CAPLUS


CN 1-Naphthalenecarboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336113-62-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-63-4 CAPLUS


CN 1-Naphthalenecarboxamide, N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-64-5 CAPLUS


CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336113-65-6 CAPLUS

CN Benzamide, 4-bromo-N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-66-7 CAPLUS

CN Benzamide, 4-bromo-N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-67-8 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1S)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-68-9 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1R)-1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-69-0 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-70-3 CAPLUS


CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-71-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336113-72-5 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-73-6 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336113-88-3 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 336114-22-8 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 336115-02-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[3-[(1-methylethyl)amino]propyl]- (9CI)  
(CA INDEX NAME)




RN 336115-04-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(4-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-06-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-09-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-3-[(3-methoxyphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-11-8 CAPLUS


CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336115-15-2 CAPLUS

CN Benzamide, N-(3-azetidinemethyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-17-4 CAPLUS

CN Benzamide, N-(2-aminoethyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-19-6 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-22-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336115-24-3 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(methylamino)propyl]- (9CI) (CA INDEX NAME)





RN 336115-26-5 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336115-28-7 CAPLUS


CN Benzamide, N-[(2R)-2-azetidinylmethyl]-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 336115-30-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-32-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(methylthio)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-36-7 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-38-9 CAPLUS


CN Benzamide, 4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336115-40-3 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-44-7 CAPLUS

CN Benzamide, N-(4-aminobutyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-46-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(3-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-48-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-56-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-58-3 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-60-7 CAPLUS

CN Benzamide, 4-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-62-9 CAPLUS

CN Benzamide, N-(4-aminobutyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-66-3 CAPLUS

CN Benzamide, N-[3-(1-azetidiny)propyl]-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-72-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 336115-74-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]butyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336115-82-3 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylthio)propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-86-7 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336115-95-8 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)




RN 336115-97-0 CAPLUS

CN Benzamide, N-(5-aminopentyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-99-2 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-03-1 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-07-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-09-7 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(diethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 336116-13-3 CAPLUS

CN Carbamic acid, [5-[(3-aminopropyl)(4-methylbenzoyl)amino]-5-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 336116-17-7 CAPLUS


CN 2-Naphthalenecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336116-19-9 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-cyclohexylethyl]-4-methyl- (9CI) (CA INDEX NAME)






RN 336116-23-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(3-hydroxypropyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-25-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336116-27-9 CAPLUS

CN Benzamide, N-(6-aminohexyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-29-1 CAPLUS

CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-31-5 CAPLUS

CN Benzamide, 4-bromo-N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-33-7 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 336116-35-9 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-37-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-39-3 CAPLUS

CN Benzamide, N-[5-amino-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]pentyl]-N-(3-aminopropyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-41-7 CAPLUS


CN Benzamide, N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-43-9 CAPLUS  
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-3-[(3-methylphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-45-1 CAPLUS  
 CN Benzamide, 4-bromo-N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336116-47-3 CAPLUS  
 CN  $\beta$ -Alanine, N-(4-bromobenzoyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-49-5 CAPLUS  
 CN 1,3-Benzodioxole-5-carboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-53-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 336116-55-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-57-5 CAPLUS

CN Benzamide, 3-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-65-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-67-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 336116-69-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-7-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-73-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 336116-75-7 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)




RN 336116-77-9 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-79-1 CAPLUS

CN Benzamide, 4-bromo-N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-81-5 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(phenylmethoxy)ethyl]-4-methyl- (9CI)  
(CA INDEX NAME)




RN 336116-83-7 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylsulfinyl)propyl]-4-methyl- (9CI)  
(CA INDEX NAME)



RN 336116-87-1 CAPLUS


CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 336116-89-3 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)






RN 336116-91-7 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-95-1 CAPLUS

CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-97-3 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336117-01-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-3-[(4-methoxyphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-03-4 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(methylsulfinyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-07-8 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336117-09-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-hydroxyethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-13-6 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)




RN 336117-21-6 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)




RN 336117-24-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(2-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-26-1 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-28-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[1-cyclohexyl-4-(diethylamino)butyl]- (9CI) (CA INDEX NAME)




RN 336117-32-9 CAPLUS

CN Benzamide, N-(2-aminoethyl)-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-34-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336117-36-3 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-fluoro-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-40-9 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-42-1 CAPLUS


CN	Benzamide, N-(3-aminopropyl)-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI)	(CA
	INDEX NAME)	




CN    Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI)    (CA INDEX NAME)




CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



CN    Benzanide, N-[3-(dimethylamino)propyl]-4-fluoro-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI)    (CA INDEX NAME)




CN    Benamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[4-(diethylamino)-1-methylbutyl]- (9CI)    (CA INDEX NAME)




RN 336117-54-5 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-7-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-56-7 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-60-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-62-5 CAPLUS

CN 6-Quinolinecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-65-8 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 336117-67-0 CAPLUS


CN Benzamide, 4-bromo-N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336117-71-6 CAPLUS


CN Benzamide, 3-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)






RN 336117-84-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(methylsulfonyl)- (9CI)  
(CA INDEX NAME)




RN 336117-86-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
(CA INDEX NAME)




RN 336118-06-0 CAPLUS

CN Benzamide, 3-bromo-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-27-5 CAPLUS

CN Benzamide, 4-cyano-N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336118-30-0 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336118-32-2 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-34-4 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 336118-36-6 CAPLUS  
 CN Benzamide, 4-cyano-N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336118-39-9 CAPLUS  
 CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




RN 336118-41-3 CAPLUS  
 CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 336118-43-5 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-45-7 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-3-[(2-methylphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-49-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336118-59-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-61-7 CAPLUS

CN Carbamic acid, [3-[(4-bromobenzoyl)[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 336118-64-0 CAPLUS

CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-74-2 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-76-4 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336118-88-8 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 336119-03-0 CAPLUS

CN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 336119-17-6 CAPLUS

CN  $\beta$ -Alanine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 336119-19-8 CAPLUS

CN Glycine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 336119-23-4 CAPLUS

CN Benzoic acid, 4-[[[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl][2-(dimethylamino)ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2; d his; log y  
 L2 HAS NO ANSWERS  
 L1 STR



Hy 1

G1 Cy,Ak  
 G2 N,CH, [01]

Structure attributes must be viewed using STN Express query preparation.  
 L2 QUE ABB=ON PLU=ON L1

(FILE 'REGISTRY' ENTERED AT 11:49:16 ON 11 MAY 2006)

DEL HIS Y  
 L1 STRUCTURE UPLOADED  
 L2 QUE L1  
 L3 9 S L2  
 L4 219 S L2 FUL

FILE 'CAPLUS' ENTERED AT 11:50:21 ON 11 MAY 2006

L5 11 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	57.13	224.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.25	-8.25

STN INTERNATIONAL LOGOFF AT 11:51:31 ON 11 MAY 2006